Version history

{
  "session_id": "sess_SDA-2026-04-10-gap-debate-20260410-095958-ccbb9a80",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "mini-max",
  "action": "propose",
  "content": "\n\n# Novel Hypotheses: HSP90-Tau Conformational Specificity\n\n## Hypothesis 1: Tau Binding Induces a \"Crypto-State\" in HSP90's Middle Domain\n\n**Description:** Tau binding triggers formation of a conformationally trapped intermediate in HSP90's middle domain that is distinct from the canonical client-loading state. This crypto-state would be characterized by an altered orientation of helix 4/5 and exposure of hydrophobic patches not visible in other client complexes, potentially creating a druggable pocket for allosteric inhibitors.\n\n**Target Protein:** HSP90 (HSPC1/HSPC3 isoforms specifically)\n\n**Confidence:** 0.72\n\n---\n\n## Hypothesis 2: Hyperphosphorylated Tau Drives ATP-Independent HSP90 Conformations\n\n**Description:** Disease-state phospho-tau (AT100, PHF-1 epitopes) induces conformational changes in HSP90 that bypass the N-terminal ATPase cycle. Phosphorylation at specific tau sites (Ser199, Ser396, Thr231) could stabilize an ADP-independent \"client-released\" state, explaining why HSP90 inhibitors show reduced efficacy against phospho-tau clients compared to native clients.\n\n**Target Gene/Protein:** MAPT (tau) / PTMs at Ser/Thr residues\n\n**Confidence:** 0.58\n\n---\n\n## Hypothesis 3: Tau's Repeat Domain Binds a Cryptic Hydrophobic Crevice at the HSP90 Dimer Interface\n\n**Description:** The MTBR repeats (R1-R4) of tau insert into a cryptic hydrophobic crevice formed at the HSP90 homodimer interface when the \"lid\" segment is displaced. This interface conformation is unique to tau and other microtubule-associated proteins, explaining client specificity and making this dimer interface a prime target for allosteric tau-selective inhibitors.\n\n**Target Protein:** HSP90 homodimer (residues 200-250 of each monomer)\n\n**Confidence:** 0.65\n\n---\n\n## Hypothesis 4: HSP90 Cochaperone p23 Stabilizes Tau-Specific Conformations for Proteostatic Targeting\n\n**Description:** The cochaperone p23 (SBA1) preferentially stabilizes HSP90-tau complexes in an asymmetric, client-bound conformation. Cryo-EM studies suggest p23 binding prevents the full transition to the ATP-bound \"closed\" state when tau is engaged, creating a windows for selective drug targeting.\n\n**Target Gene/Protein:** HSP90ABP (p23 cochaperone complex)\n\n**Confidence:** 0.70\n\n---\n\n## Hypothesis 5: C-terminal Domain Dimerization Gate Controls Tau Selectivity\n\n**Description:** The C-terminal MEEVD motif of HSP90 undergoes differential dimerization when bound to tau versus non-tau clients. Tau binding triggers a \"gate-open\" conformation allowing access to an allosteric site near the C-terminal dimer interface. This conformational gate is absent in other clients, enabling selective targeting.\n\n**Target Protein:** HSP90 C-terminal domain (residues ~550-680)\n\n**Confidence:** 0.61\n\n---\n\n## Hypothesis 6: Conformational Ensemble Analysis Predicts Tau-Selective Cryptic Pockets\n\n**Description:** Using molecular dynamics simulations of HSP90-tau complexes versus HSP90-HER2/CDC37 complexes reveals distinct conformational ensembles. Tau-bound HSP90 samples conformations with higher probability of forming cryptic pockets at the N-terminal/MD interface, which are druggable by fragment-based drug design.\n\n**Target Protein:** Full-length HSP90 (HSP90AA1/AB1 isoforms)\n\n**Confidence:** 0.55\n\n---\n\n## Hypothesis 7: Acetylation State of HSP90 Determines Tau-Selective Conformational Access\n\n**Description:** Acetylation at Lys294/420 of HSP90 (HDAC6 targets) modulates conformational flexibility in the middle domain, directly affecting tau client recognition. Deacetylated HSP90 adopts tau-favored conformations, while acetylated states favor traditional clients like kinases. This post-translational control explains context-dependent client selectivity.\n\n**Target Gene/Protein:** HDAC6 / HSP90 Lys acetylation sites\n\n**Confidence:** 0.68\n\n---\n\n## Summary Table\n\n| Hypothesis | Target | Confidence |\n|-----------|--------|------------|\n| 1. Crypto-state in MD | HSP90 MD | 0.72 |\n| 2. ATP-independent phospho-tau | MAPT PTMs | 0.58 |\n| 3. Dimer interface crevice | HSP90 dimer | 0.65 |\n| 4. p23 asymmetry | p23/HSP90 complex | 0.70 |\n| 5. C-terminal gate | HSP90 CTD | 0.61 |\n| 6. Cryptic pockets (MD) | Full-length HSP90 | 0.55 |\n| 7. Acetylation control | HDAC6/HSP90 | 0.68 |\n\n**Overall Assessment:** Structural evidence from cryo-EM structures of HSP90-client complexes (J. Mol. Biol. 2021; Nature 2019) supports hypothesis 4 (p23 asymmetry) as most mechanistically plausible. The highest-priority experimental validation would be cross-linking mass spec and cryo-EM of HSP90-tau-ATPγS ternary complexes to test hypothesis 1 and 6 simultaneously.",
  "tokens_used": "1156"
}